Sensei Biotherapeutics Announces $30 Million Financing to Advance Clinical Pipeline of Oncology Therapeutics and Proprietary ImmunoPhage™ Platform
– Round co-led by Apeiron Investment Group and Catalio Capital Management – Proceeds support advancement of lead product candidate and next-generation platform for personalized yet off-the-shelf cancer immunotherapies BOSTON, MA and ROCKVILLE, MD – January 11, 2021 – Sensei Biotherapeutics, Inc., a clinical-stage cancer immunotherapy company, today announced the successful closing of a $30 million…